FDA Should Have Larger Role In Trade Talks, Hamburg Says

This article was originally published in The Pink Sheet Daily

01 Oct 2012
News

Sue Sutter @PinkSheetSutter sue.sutter@informa.com

Executive Summary

FDA commissioner believes the agency needs to have “a full place at the table,” rather than being summoned into the process late and viewed as obstructionist when it raises public health concerns.

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

Topics

United States

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

BioPharmaceutical United States Asia Pacific

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS073331

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS073331

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

FDA Should Have Larger Role In Trade Talks, Hamburg Says

News

Executive Summary

Related Content

U.S. FDA Wary About “Paying The Price” For Mistakes Based On Foreign Data

Foreign Regulatory Systems Can Be Strengthened By Receiving FDA Inspection Data, IOM Says

Topics

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert